In breast cancer cell lines, MDGI plays an important role in EGFR subcellular relocalization into an intracellular pool where the receptor is active but in a compartment that renders anti-EGFR antibody therapy inefficient [3]. This evidence concerns the gene FABP3 and breast carcinoma.